Results 211 to 220 of about 10,777 (280)

Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study. [PDF]

open access: yesBlood Cancer J
Hansen DK   +29 more
europepmc   +1 more source

Does Palsa Thaw in Northern Finland Contribute to Remobilisation of Metals Accumulated in Peat Into Surface Waters?

open access: yesLand Degradation &Development, Volume 37, Issue 9, Page 4230-4250, 30 May 2026.
ABSTRACT Permafrost is rapidly degrading in the sporadic zone, including palsa mires in Scandinavia. Peatlands in the area have likely accumulated heavy metals from atmospheric deposition of industrial contaminants in the wider region. As the palsa mire chemical composition is not well known, and in other permafrost regions the permafrost thaw may ...
Joanna Katarzyna Jóźwik   +7 more
wiley   +1 more source

Youth partner engagement in the development of an integrated care pathway for the treatment of adolescents with depression. [PDF]

open access: yesJ Can Acad Child Adolesc Psychiatry
Prebeg M   +7 more
europepmc   +1 more source

Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: a quaternary cancer center cohort. [PDF]

open access: yesBlood Cancer J
Ali HM   +21 more
europepmc   +1 more source

CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting. [PDF]

open access: yesTransplant Cell Ther
Hunter BD   +18 more
europepmc   +1 more source

Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma. [PDF]

open access: yesJ Clin Oncol
Jagannath S   +32 more
europepmc   +1 more source

The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience. [PDF]

open access: yesBlood Cancer J
Afrough A   +45 more
europepmc   +1 more source

Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. [PDF]

open access: yesJ Clin Oncol
Neelapu SS   +22 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy